Skip to main content

Stem Cell Therapy for Erectile Dysfunction

Stem cell therapy (SCT) for erectile dysfunction is a promising but still investigational regenerative approach intended to restore rather than palliate — regenerating smooth muscle, endothelium, and cavernous-nerve function rather than masking the deficit. The AUA 2018 guideline classifies intracavernosal stem cell therapy as investigational (Conditional Recommendation; Evidence Level Grade C); randomized sham-controlled trials do not yet clearly indicate that benefits reliably outweigh risks / burdens, and no stem cell product is currently FDA-approved for ED.[1]

AUA 2018 — investigational only; commercial-clinic risk

"For men with ED, intracavernosal stem cell therapy should be considered investigational (Conditional Recommendation; Evidence Level Grade C)."[1]

Counsel patients that SCT for ED should only be pursued within approved clinical trials. Unregulated clinics market stem-cell injections for ED without adequate evidence — a documented patient-safety and ethical concern.[2]

Rationale and target populations​

Conventional ED treatments (PDE5i, ICI, VED) provide symptomatic relief but do not reverse underlying pathology — smooth-muscle degeneration, endothelial dysfunction, cavernous-nerve injury, and corporal fibrosis. SCT aims to be restorative.[3][4]

Populations with the greatest unmet need and most active research:[5][6]

  • Post-radical-prostatectomy ED (cavernous nerve injury)
  • Diabetic ED (vasculogenic + neuropathic)
  • PDE5i-refractory ED of any etiology

Cell sources​

Multiple cell sources have been investigated, each with distinct trade-offs[6][7]:

SourceNotes
Adipose-derived stem cells (ADSCs)Most commonly used in clinical trials; harvested via liposuction; abundant yield
Bone-marrow-derived MSCs (BMSCs)Well-studied; require bone-marrow aspiration
Bone-marrow mononuclear cells / concentrateMinimally manipulated; point-of-care processing
Umbilical-cord-blood MSCs (CBMSCs)Allogeneic, low immunogenicity; preclinical superior neurotrophic-factor secretion vs ADSCs[8]
Placenta-derived MSCsRecent clinical-trial data (Ji 2025)[9]
Urine-derived stem cells (UDSCs)Non-invasive harvest; preclinical only[6]
Dental pulp stem-cell conditioned medium (SHED-CM)Acellular; uses paracrine factors (Koga 2022)[10]

Mechanism — predominantly paracrine​

The therapeutic effect is believed to be paracrine rather than direct cellular differentiation[7][6][4]:

  1. Paracrine signaling — VEGF, BDNF, NGF, IGF-1 secretion → angiogenesis, neuroregeneration, smooth-muscle repair.
  2. Anti-fibrotic effects — reduced collagen deposition; improved smooth-muscle-to-collagen ratio in corpora cavernosa.
  3. Anti-inflammatory / immunomodulatory — reduced oxidative stress and inflammatory cytokines.
  4. Endothelial repair — restoration of eNOS / nNOS expression; improved NO–cGMP signaling.
  5. Recruitment of endogenous progenitor cells — host-driven repair.
  6. Extracellular vesicles (EVs / exosomes) — bioactive cargo (mRNA, miRNA, proteins) mediating tissue repair even without intact-cell transplantation.[7]

Routes of administration​

RouteNotes
Intracavernosal injection (ICI)The predominant route in clinical trials — direct delivery to the corpus cavernosum[11]
Intravenous (systemic)Used in Nguyen Thanh 2021 ADSC trial for sexual dysfunction[12]
TransendocardialSecondary ED outcomes from cardiac stem-cell trials (Ory 2020)[13]
Periprostatic / peri-neural with scaffoldPreclinical models loading scaffold-bound stem cells onto injured cavernous nerves[14]

Clinical trial evidence​

Published human data remain limited — primarily Phase I safety trials with small samples. A comprehensive review identified 27 registered trials, only 9 with published results as of 2021 and data on fewer than 100 total patients.[15]

StudyCell typenPopulationRouteKey outcomesFollow-up
Haahr 2018[16]Autologous ADRCs21Post-RP EDICI53% (8/15) continent men achieved erections sufficient for intercourse; IIEF-5 6 → 8 at 12 mo12 mo
You 2021[5]Autologous BMSCs10Post-RP + DM EDICIIIEF 18.1 → 24.9 at 1 mo (p = 0.02); safe; no related SAEs6 mo
Bieri 2020 (Caverstem)[17]Autologous BM concentrate140 (40 trial + 100 registry)PDE5i-refractoryICIIIEF-5 +2 to +9 (protocol-dependent); peak at 3 mo12 mo
Nguyen Thanh 2021[12]Autologous ADSCs15Sexual dysfunctionIVTestosterone increased; sexual satisfaction improved; no SAEs12 mo
Koga 2022 (acellular)[10]SHED-CM38Mixed EDICI97.4% improved; IIEF-5 13.1 → 19.3; 47.4% achieved IIEF-5 ≥ 21Variable
Ory 2020 post-hoc[13]Allogeneic / autologous MSCs / BM-MNCs36Ischemic CMP + EDTransendocardial200M-cell dose: IIEF-EF 14 → 20 (p = 0.014); autologous source superior12 mo
Ji 2025 RCT[9]Placenta-derived MSCs ± LI-ESWT33Diabetic EDICI + ESWTCombined therapy: 70% achieved EHS > 2 at 6 mo; superior to monotherapy6 mo

Network meta-analysis — SCT vs other regenerative therapies​

Hinojosa-Gonzalez 2024 Bayesian network meta-analysis of 16 RCTs / 907 patients comparing SCT, PRP, and LI-ESWT[18]:

TherapySMD vs control95% CrISignificance
Stem cell therapy0.92−0.49 to 2.3Not significant (wide CrI; few RCTs; high heterogeneity)
PRP0.830.15 to 1.5Significant
LI-ESWT0.840.49 to 1.2Significant

The non-significance for SCT reflects the small number of RCTs and high heterogeneity. LI-ESWT currently has the most robust evidence base among regenerative therapies.[18]

Safety​

Across all published clinical trials, SCT for ED has demonstrated a favorable short-term safety profile:[5][11][16][17]

  • No serious adverse events directly attributable to SCT.
  • Minor AEs: bruising at harvest / injection site, transient pyrexia, back pain (BM aspiration), mild local pain.
  • No tumor formation, ectopic tissue growth, or systemic complications in published ED trials.
  • Long-term safety beyond 12 months remains unestablished.

Combination therapies — emerging signal​

Combining SCT with other regenerative modalities may be synergistic[4][9]:

  • SCT + LI-ESWT — Ji 2025 RCT of placenta-derived MSCs + LI-ESWT in diabetic ED: 70% EHS > 2 at 6 mo vs each monotherapy.[9]
  • SCT + PRP — overlapping but complementary mechanisms; PRP provides concentrated growth factors that may enhance SC survival and engraftment.[4]
  • SCT + hydrogen sulfide donors (NaHS) — preclinical synergistic improvement in cavernous-nerve-injury models (Asker 2025).[19]

Current barriers​

Critical barriers to SCT becoming standard of care[3][7][15]:

  1. Lack of large randomized placebo-controlled trials — most published data are Phase I with small samples and short follow-up.
  2. Heterogeneity in cell source, dose, processing, delivery route, and outcome measures across studies.
  3. Optimal cell source undetermined — head-to-head comparisons of cell types in humans are lacking.
  4. Optimal dosing and re-treatment interval unknown.
  5. Long-term durability and safety not established.
  6. Cost-effectiveness unstudied.
  7. Commercial exploitation — unregulated clinics market SCT for ED without adequate evidence.[2]

Guideline position​

BodyPosition
AUA 2018[1]Investigational (Conditional Recommendation; Grade C); pursue only within approved clinical trials

When to refer / when not to use​

  • Refer to a clinical trial: PDE5i-refractory ED in motivated patients with realistic expectations; post-RP ED with intact cavernous-nerve anatomy; diabetic ED with adequate metabolic control.
  • Do not offer outside trials: routine clinical use is not supported by the evidence; commercial-clinic SCT is not equivalent to trial-grade therapy and should be discouraged.[2]
  • Consider LI-ESWT or PRP first for the regenerative-therapy-curious patient — both have stronger RCT evidence and significant pooled SMD vs control.[18]

Postoperative / post-procedural management​

  • Activity restriction. Standard ICI restrictions; no specific post-SCT activity guidelines have been validated.
  • PDE5i bridging is commonly used in trial protocols.
  • PRO assessment. IIEF / IIEF-5 / EHS at baseline, 1 mo, 3 mo, 6 mo, 12 mo per the major trial protocols.
  • Counseling. Patients must be told preoperatively that SCT is investigational, not FDA-approved, and that long-term safety / durability remain undefined.

See Also​

References​

1. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–641. doi:10.1016/j.juro.2018.05.004

2. Israeli JM, Lokeshwar SD, Efimenko IV, Masterson TA, Ramasamy R. The potential of platelet-rich plasma injections and stem cell therapy for penile rejuvenation. Int J Impot Res. 2022;34(4):375–382. doi:10.1038/s41443-021-00482-z

3. Wang B, Gao W, Zheng MY, Lin G, Lue TF. Recent advances in stem cell therapy for erectile dysfunction: a narrative review. Expert Opin Biol Ther. 2023;23(6):565–573. doi:10.1080/14712598.2023.2203811

4. Towe M, Peta A, Saltzman RG, et al. The use of combination regenerative therapies for erectile dysfunction: rationale and current status. Int J Impot Res. 2022;34(8):735–738. doi:10.1038/s41443-021-00456-1

5. You D, Jang MJ, Song G, et al. Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial. Cytotherapy. 2021;23(10):931–938. doi:10.1016/j.jcyt.2021.06.001

6. Fu X, Sheikholeslami A, Zhanbyrbekuly U, et al. Advances in stem cell therapy for erectile dysfunction: preclinical evidence and emerging therapeutic approaches. Front Med. 2025;12:1519095. doi:10.3389/fmed.2025.1519095

7. Patel AA, Shafie A, Mohamed AH, et al. The promise of mesenchymal stromal/stem cells in erectile dysfunction treatment: a review of current insights and future directions. Stem Cell Res Ther. 2025;16(1):98. doi:10.1186/s13287-025-04221-9

8. Ti Y, Yang M, Chen X, et al. Comparison of the therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells and adipose-derived stem cells on erectile dysfunction in a rat model of bilateral cavernous nerve injury. Front Bioeng Biotechnol. 2022;10:1019063. doi:10.3389/fbioe.2022.1019063

9. Ji YH, Zhang YF, Tan X, et al. High-activity placenta-derived mesenchymal stem cells combined with low-intensity extracorporeal shock wave therapy for diabetic erectile dysfunction: a prospective randomized controlled trial. Stem Cell Res Ther. 2025;16(1):359. doi:10.1186/s13287-025-04499-9

10. Koga S, Horiguchi Y. Efficacy of a cultured conditioned medium of exfoliated deciduous dental pulp stem cells in erectile dysfunction patients. J Cell Mol Med. 2022;26(1):195–201. doi:10.1111/jcmm.17072

11. Hansen ST, Lund M, Ostergaard LD, Lund L. Role of regenerative therapies on erectile dysfunction after radical prostatectomy. Int J Impot Res. 2021;33(4):488–496. doi:10.1038/s41443-020-00406-3

12. Nguyen Thanh L, Dam PTM, Nguyen HP, et al. Can autologous adipose-derived mesenchymal stem cell transplantation improve sexual function in people with sexual functional deficiency? Stem Cell Rev Rep. 2021;17(6):2153–2163. doi:10.1007/s12015-021-10196-w

13. Ory J, Saltzman RG, Blachman-Braun R, et al. The effect of transendocardial stem cell injection on erectile function in men with cardiomyopathy: results from the TRIDENT, POSEIDON, and TAC-HFT trials. J Sex Med. 2020;17(4):695–701. doi:10.1016/j.jsxm.2020.01.003

14. Hu D, Liu C, Ge Y, et al. Poly-L-lactic acid/gelatin electrospun membrane-loaded bone marrow-derived mesenchymal stem cells attenuate erectile dysfunction caused by cavernous nerve injury. Int J Biol Macromol. 2024;265(Pt 2):131099. doi:10.1016/j.ijbiomac.2024.131099

15. He M, von Schwarz ER. Stem-cell therapy for erectile dysfunction: a review of clinical outcomes. Int J Impot Res. 2021;33(3):271–277. doi:10.1038/s41443-020-0279-8

16. Haahr MK, Harken Jensen C, Toyserkani NM, et al. A 12-month follow-up after a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. Urology. 2018;121:203.e6–203.e13. doi:10.1016/j.urology.2018.06.018

17. Bieri M, Said E, Antonini G, et al. Phase I and registry study of autologous bone marrow concentrate evaluated in PDE5 inhibitor refractory erectile dysfunction. J Transl Med. 2020;18(1):24. doi:10.1186/s12967-019-02195-w

18. Hinojosa-Gonzalez DE, Saffati G, Orozco Rendon D, et al. Regenerative therapies for erectile dysfunction: a systematic review, Bayesian network meta-analysis, and meta-regression. J Sex Med. 2024;21(12):1152–1158. doi:10.1093/jsxmed/qdae131

19. Asker H, Sezen SF, Yilmaz-Oral D, et al. The beneficial effects of adipose-derived stem cell and hydrogen sulfide donor sodium hydrogen sulfide combination therapy on erectile dysfunction in a rat model of radical prostatectomy. Eur J Pharmacol. 2025;1001:177760. doi:10.1016/j.ejphar.2025.177760